Bevacizumab · injectable solution
Injections & Implants
OFF-LABELNot in the FDA label for this product
Neovascular (wet) age-related macular degeneration
1.25 mg in 0.05 mL by intravitreal injection, typically monthly or as needed on OCT and acuity review
RCT, n=1185
The CATT trial randomized patients with neovascular AMD to bevacizumab or ranibizumab, monthly or as-needed. At two years bevacizumab and ranibizumab produced equivalent effects on visual acuity when given on the same schedule, and as-needed dosing produced less gain than monthly dosing for both drugs.
Diabetic macular edema and macular edema following retinal vein occlusion
1.25 mg in 0.05 mL by intravitreal injection, repeated on OCT and acuity review
RCT, n=660
Protocol T compared aflibercept, bevacizumab and ranibizumab for center-involved diabetic macular edema. At one year all three improved vision; aflibercept was more effective than bevacizumab where baseline acuity was 20/50 or worse, and the three were comparable where baseline acuity was better than that.
Contraindications
None.
Injection, supplied for intravenous oncology use as 100 mg/4 mL and 400 mg/16 mL single-dose vials. Ophthalmic use requires compounding into single-use syringes by a compounding pharmacy.
Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors Flt-1 and KDR on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and new blood vessel formation in in vitro models of angiogenesis.
Warnings & Precautions
- Compounding: the ophthalmic product does not come from the manufacturer. Clusters of endophthalmitis have been traced to compounding failures, so the pharmacy matters as much as the technique.
- Intravitreal injection: it carries a risk of endophthalmitis, retinal detachment and raised intraocular pressure.
- Intravenous label warnings: gastrointestinal perforation, surgery and wound healing complications, and hemorrhage lead the intravenous label's warnings, which carry no boxed warning; these belong to systemic dosing, which is orders of magnitude above the intravitreal dose.
- PRES (intravenous label): posterior reversible encephalopathy syndrome was reported in under 0.5% of patients, with onset 16 hours to 1 year after the first dose. It can present with headache, seizure, lethargy, confusion, blindness and other visual and neurologic disturbances, sometimes with hypertension. MRI is needed to confirm it; stop Avastin if it develops.
- Arterial thromboembolic events: these have been reported after intravitreal VEGF inhibition, though causality is unsettled.
Common Side Effects
Ocular, after intravitreal injection: conjunctival hemorrhage, eye pain, floaters and raised intraocular pressure, with endophthalmitis and retinal detachment as rare but serious events. Systemic, from the oncologic intravenous use: the most common reactions, at a rate above 10%, are epistaxis, headache, hypertension, rhinitis, proteinuria, taste alteration, dry skin, hemorrhage, lacrimation disorder, back pain, and exfoliative dermatitis.
Pregnancy: Avastin may cause fetal harm in pregnant women. Limited postmarketing reports describe cases of fetal malformations with use of Avastin in pregnancy; however, these reports are insufficient to determine drug-associated risks. Advise females of reproductive potential to use effective contraception during treatment with Avastin and for 6 months after the last dose.
Lactation: No data are available regarding the presence of bevacizumab in human milk. Because of the potential for serious adverse reactions in breastfed infants, advise women not to breastfeed during treatment with Avastin and for 6 months after the last dose.
Safety and effectiveness in pediatric patients have not been established. Avastin is not approved for use in patients under the age of 18 years. In published literature reports, cases of non-mandibular osteonecrosis have been observed in patients under the age of 18 years who received Avastin. Intravitreal bevacizumab has been used off-label in retinopathy of prematurity, where systemic VEGF suppression and its effect on developing organs remain a subject of study.